The Water-Soluble Extract from Cultured Medium of Ganoderma lucidum (Reishi) Mycelia (Designated as MAK) Ameliorates Murine Colitis Induced by Trinitrobenzene Sulphonic Acid

Scandinavian Journal of Immunology

Volumn 74, Issue 5, 2011, Pages 454-462

  Hanaoka, R ^a   Ueno, Y ^b   Tanaka, S ^b   Nagai, K ^a   Onitake, T ^a   Yoshioka, K ^a   Chayama, K ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GANODERMA LUCIDUM EXTRACT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENTERY LYMPH NODE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; COLITIS; COLON; CULTURE MEDIA; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MYCELIUM; REISHI; TRINITROBENZENESULFONIC ACID;

EID: 80053519297     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02601.x     Document Type: Article

References (42)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evoking therapies. Lancet 2007;369:1641-57.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
3. Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009;206:1839-43.
4. Segal AW, Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet 1976;2:219-21.
5. Marks DJ, Harbord MW, MacAllister R et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367:668-78.
6. Hugot JP, Chamaillard M, Zouai H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
7. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn's disease in ATG16L1. Nat Genet 2007;39:207-11.
8. Dieckgraefe BK, Korzenik JR, Anant S. Growth factors as treatment options for intestinal inflammation. Ann N Y Acad Sci 2006;1072:300-6.
9. Cadwell K, Liu J, Brown SL et al. A unique role for autophagy and ATG16L1 in paneth cells in murine and human intestine. Nature 2008;456:259-63.
10. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterol 2007;13:5577-80.
11. Lin ZB. Pharmacological functions of Ganoderma lucidum. In: Lin ZB, ed. Modern Research of Ganoderma lucidum, 2nd edn. Beijing: Beijing Medical University Press, 2001:284-309.
12. Yeung WH, Lu QY, Zang Q, Go VLW. Chemical and biochemical basis of the potential anti-tumor properties of Ganoderma lucidum. Curr Top Nutraceutical Res 2004;2:67-77.
13. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep 2003;10:375-9.
14. Kashimoto N, Hayama M, Kamiya K, Watanabe H. Inhibitory effect of a water-soluble extract from the culture medium of Ganoderma lucidum (Rei-shi) mycelia on the development of pulmonary adenocarcinoma induced by N-nitrosobis (2-hydroxypropyl) amine in Wistar rats. Oncol Rep 2006;16:1181-7.
15. Chang YH, Yang JL, Wu CL et al. Ganoderma lucidum extract promotes immune responses in normal BALB/c mice In vivo. In Vivo 2009;23:755-9.
16. Ahmadi K, Riazipour M. Ganoderma lucidum induces the expression of CD40/CD86 on peripheral blood monocytes. Iran J Immunol 2009;6:87-91.
17. Zhu XL, Lin ZB. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells. Acta Pharmacol Sin 2005;26:1130-7.
18. Chen HS, Tsai YF, Lin S et al. Studies on the immune-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem 2004;12:5595-601.
19. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
20. Han X, Uchida K, Jurickova I et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 2009;136:1261-71.
21. Santucci L, Fiorucci S, Rubinstein N et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 2003;124:1381-94.
22. Oka S, Tanaka S, Yoshida S et al. A water-soluble extract from cultured medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci 2010;59:1-6.
23. Sone Y, Okuda R, Wada N, Kishida E, Misaki A. Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of Mycelium of Ganoderma lucidum. Agric Biol Chem 1985;49:2641-53.
24. Nameda S, Harada T, Miura NN et al. Enhanced cytokine synthesis of leukocytes by a beta-glucan preparation, SCG, extracted from a medicinal mushroom, Sparassis crispa. Immunopharmacol Immunotoxicol 2003;25:321-35.
25. Lin ZB. Cellular and molecular mechanisms of immunomodulation by Ganoderma lucidum. J Pharmacol Sci 2005;99:144-53.
26. Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 2007;13:5581-93.
27. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-8.
28. Mencarelli A, Renga B, Palladino G, Distrutti E, Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochem Pharmacol 2009;78:1214-23.
29. Coquerelle C, Oldenhove G, Acolty V et al. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009;58:1363-73.
30. Sainathan SK, Hanna EM, Gong Q et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis 2007;14:88-99.
31. Bernasconi E, Favre L, Maillard MH et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis 2010;16:428-41.
32. Xu Y, Hunt NH, Bao S. The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res 2008;18:1220-9.
33. Paine R III, Preston AM, Wilcoxen S et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol 2000;164:2602-9.
34. Hirata Y, Egea L, Dann SM, Eckmann L, Kagnoff MF. GM-CSF-facilitated dendritic cell recruitment and survival govern the intestinal mucosal response to a mouse enteric bacterial pathogen. Cell Host Microbe 2010;7:151-63.
35. Harada T, Ohno N. Contribution of dectin-1 and granulocyte macrophage-colony stimulating factor (GM-CSF) to immunomodulating actions of beta-glucan. Int Immunopharmacol 2008;8:556-66.
36. Usui T, Iwasaki Y, Mizuno T. Isolation and characterization of antitumor active beta-D-glucans from the fruit bodies of Ganoderma applanatum. Carbohydr Res 1983;115:273-80.
37. Miyazaki T, Nishijima M. Structural examination of an alkali-extracted, water-soluble heteroglycan of the fungus Ganoderma lucidum. Carbohydr Res 1982;109:290-4.
38. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008;8:533-44.
39. Fukuzawa H, Sawada M, Kayahara T et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun 2003;312:897-902.
40. Bamias G, Cominelli F. Novel strategies to attenuate immune activation in Crohn's disease. Curr Opin Pharmacol 2006;6:401-7.
41. Wilk JN, Viney JL. GM-CSF treatment for Crohn's disease: a stimulating new therapy? Curr Opin Investig Drugs 2002;3:1291-6.
42. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. N Eng J Med 2005;352:2193-201.